Medtronic Launches New Clinician Programmer for Deep Brain Stimulation Therapy

(June 15, 2018) – Medtronic, the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) recently approved its state-of-the art Deep Brain Stimulation (DBS) Clinician Programmer and Activa(TM)Programming Application. This programmer will have an immediate impact to the programming interactions that are a critical part of post-implant care for thousands of patients. The programmer will also enable the upgrade of Activa rechargeable implantable neurostimulators service life to 15 years, giving patients an additional 6 years until their next device replacement. Read more…